The combination of teclistamab and daratumumab has been studied in patients with relapsed or refractory multiple myeloma. Teclistamab is a bispecific antibody targeting BCMA and CD3 that shows high efficacy in the treatment of this form of myeloma. Daratumumab is a monoclonal antibody against CD38 that has shown a positive effect in several clinical trials in patients with relapsed or refractory myeloma. The combination of these two drugs uses different mechanisms of action, which can lead to a higher treatment response, including complete remissions. Studies have confirmed a good tolerability and a manageable side effect profile, with daratumumab mainly causing infusion-related reactions that decrease over time. Patients treated with teclistamab had a median progression-free survival of around 9.4 months, with reduced dosing not significantly affecting treatment efficacy. This combination therapy represents a promising approach in the treatment of patients with difficult-to-treat multiple myeloma who have already undergone multiple previous therapies.